Videx (Didanosine, ddI)
| Brand Name: |
Videx EC |
| Generic Name: |
Didanosine, ddI |
| Adult Single Dose: |
Patients weighing at least 133 lbs
(60 kg): one 400-mg capsule (once a day)
Patients weighing less than 133 lbs (60 kg): one 250-mg capsule (once a day) |
| Food & Liquid Restrictions: |
Take on an empty stomach,
at least 30 minutes before or two hours after eating or drinking, except
water. Do not take Videx EC with food. |
| Drug Class: |
NRTI |
The Basics
- An Overview of Videx (Didanosine, ddI) (Regularly Updated)
From AIDSinfo
- Didanosine (Videx, ddI) (January 31, 2010)
To read PDF, click here.
From AIDS InfoNet
- Patient Information About Videx (Didanosine, ddI) (PDF) (June 2009)
From Bristol-Myers Squibb Company
- Videx EC (March/April 2009)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Videx EC (Didanosine, ddI EC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- ddI (Videx, didanosine) (August 15, 2006)
From AIDS Treatment Data Network
News
Research
- Emtriva + Reyataz + Videx Not as Effective as Combivir + Sustiva in First-Line Therapy, Study Finds (May 28, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds (February 5, 2008)
An interview with Jens Lundgren, M.D.
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
From HIV i-Base
- Position Statement by the D:A:D Steering Committee (February 4, 2008)
A discussion of the significance of a study examining the association between use of abacavir, didanosine and lamivudine and the risk of myocardial infarction.
To read PDF, click here.
From D:A:D Steering Committee
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- ddI + Ribavirin May Cause Mitochondrial Toxicity (September 1, 2005)
In Journal of Acquired Immune Deficiency Syndromes
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here.
From U.S. Food and Drug Administration
|
|
Advertisement
|
E-Mail
Glossary
Share
